Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.

Source:http://linkedlifedata.com/resource/pubmed/id/19839938

Endocr Metab Immune Disord Drug Targets 2010 Mar 1 10 1 1-7

Download in:

View as

General Info

PMID
19839938